broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K70401845-001-15-7 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 1.222974 | 0.007883 | -0.05209 | 1 | 1,288.38657 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000962 |
BRD-K73838513-003-05-5 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.825029 | 1.628879 | 0.155348 | 0.945264 | 0.482424 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000962 |
BRD-K74514084-003-09-2 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.728073 | 0.992516 | 0.226287 | 0.915451 | 0.514564 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000962 |
BRD-K75009076-001-02-1 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.109595 | 5.129353 | 0.479742 | 0.871205 | 2.457101 | 2.578529 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000962 |
BRD-K76210423-001-01-6 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.778881 | 0.565289 | 0.077869 | 0.933711 | 0.766738 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000962 |
BRD-K76239644-001-02-6 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.172236 | 2.156326 | 0.789762 | 0.80569 | 1.028327 | 1.2508 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000962 |
BRD-K76674262-001-03-3 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.113711 | 4.741132 | 0.783007 | 0.660018 | 0.241681 | 0.255201 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000962 |
BRD-K77625799-001-07-7 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.210047 | 3.371234 | 0.646349 | 0.887694 | 2.523758 | 2.96647 | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000962 |
BRD-K78431006-001-15-1 | ACH-000962 | OC314_OVARY | MTS010 | 1 | -0.065776 | 3.767048 | 0.574491 | 0.966309 | 8.134989 | 7.872566 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000962 |
BRD-K79254416-001-21-8 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.301216 | 3.402265 | 0.757303 | 0.814414 | 0.759751 | 0.996351 | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000962 |
BRD-K81016934-001-02-0 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.697872 | 3.136454 | 0.193941 | 0.98483 | 6.64091 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000962 |
BRD-K81418486-001-44-2 | ACH-000962 | OC314_OVARY | MTS010 | 1 | -0.496765 | 34.322965 | 0.649971 | 0.996459 | 9.947226 | 9.749275 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000962 |
BRD-K81473043-001-19-5 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.301339 | 8.322818 | 0.755427 | 0.850198 | 0.078008 | 0.087158 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000962 |
BRD-K82135108-001-04-3 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.318016 | 5.306496 | 0.536184 | 0.769517 | 0.376367 | 0.455341 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000962 |
BRD-K82746043-001-19-3 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 1.159943 | 0.419136 | 0.02271 | 1 | 0.005115 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000962 |
BRD-K82818427-001-04-8 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 1.323383 | -0.660752 | 0.284605 | 1 | 0.004599 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000962 |
BRD-K83029223-001-01-3 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.141303 | 1.929636 | 0.906738 | 0.506771 | 0.00237 | 0.002815 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000962 |
BRD-K83988098-001-02-0 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.050714 | 0.742635 | 0.470598 | 0.713224 | 0.009693 | 0.011195 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000962 |
BRD-K85402309-043-01-9 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.186438 | 4.592722 | 0.700166 | 0.85603 | 1.79555 | 1.987563 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000962 |
BRD-K85606544-001-09-1 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.244907 | 0.43733 | 0.222352 | 0.751135 | 0.680846 | 3.172175 | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000962 |
BRD-K86118762-001-01-8 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.705835 | 0.107714 | -0.054102 | 0.906254 | 105.301342 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000962 |
BRD-K86972824-001-01-4 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.438129 | 0.140294 | 0.038617 | 0.929973 | 127,131.575964 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000962 |
BRD-K87737963-001-06-0 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.078471 | 1.326395 | 0.629782 | 0.841344 | 2.051943 | 2.333798 | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000962 |
BRD-K87782578-001-01-4 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.130017 | 4.191634 | 0.749291 | 0.932273 | 4.746309 | 5.099868 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000962 |
BRD-K87909389-003-03-4 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.148818 | 0.823215 | 0.799387 | 0.527598 | 0.044862 | 0.068909 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000962 |
BRD-K88510285-001-17-8 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.119227 | 2.125414 | 0.926592 | 0.607656 | 0.033201 | 0.037741 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000962 |
BRD-K89014967-001-04-3 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.343328 | 0.316224 | 0.377433 | 0.726437 | 0.276491 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000962 |
BRD-K92441787-001-04-1 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.731695 | -1.410939 | 0.009671 | 0.973131 | 0.00131 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000962 |
BRD-K92723993-001-17-4 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.871137 | 0.123153 | -0.011767 | 0.972998 | 4,962.930236 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000962 |
BRD-K95142244-001-01-5 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.110175 | 1.302883 | 0.911017 | 0.594711 | 0.120519 | 0.145887 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000962 |
BRD-K96123349-236-02-8 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.985253 | 0.502242 | 0.00327 | 0.991881 | 0.043456 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000962 |
BRD-K98572433-001-02-9 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.815579 | 9.432906 | 0.09111 | 0.881596 | 0.019682 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000962 |
BRD-K99113996-001-02-0 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.095544 | 0.635519 | 0.796383 | 0.732688 | 0.734268 | 1.025116 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000962 |
BRD-K99616396-001-05-1 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.905776 | 0.722866 | 0.087693 | 0.955827 | 0.107724 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000962 |
BRD-K99749624-001-07-0 | ACH-000962 | OC314_OVARY | MTS010 | 1 | -1.876269 | 3.728752 | 0.382493 | 0.991813 | 18.142182 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000962 |
BRD-M97302542-001-04-4 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.916676 | 1.083935 | -0.056967 | 0.970598 | 0.33287 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000962 |
BRD-A25234499-001-19-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.149135 | -0.300339 | -0.02177 | 1 | 1.112062 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000965 |
BRD-A70858459-001-01-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.206597 | 2.958893 | 0.505545 | 0.909302 | 3.340509 | 3.999944 | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000965 |
BRD-A74914197-001-02-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.882784 | 1.854658 | -0.041908 | 0.934568 | 0.002773 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000965 |
BRD-K02113016-001-19-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.526583 | 0.1608 | 0.015326 | 0.781424 | 0.212833 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000965 |
BRD-K02130563-001-11-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.118023 | 2.373624 | 0.818926 | 0.397968 | 0.013273 | 0.014867 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000965 |
BRD-K03390685-001-01-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.227432 | 1.088499 | 0.812624 | 0.625806 | 0.091053 | 0.158991 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000965 |
BRD-K03406345-001-21-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.277032 | 0.413322 | 0.176879 | 0.697243 | 0.221009 | 1.559428 | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000965 |
BRD-K03765900-001-01-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | -0.162147 | 0.312255 | 0.568604 | 0.623612 | 1.248163 | 0.50771 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000965 |
BRD-K05804044-001-18-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.158172 | 0.635916 | 0.515614 | 0.68302 | 0.294211 | 0.535028 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000965 |
BRD-K06814349-304-02-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.090161 | 1.165079 | 0.79313 | 0.653273 | 0.250353 | 0.296944 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000965 |
BRD-K08109215-001-06-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.974462 | -1.104852 | -0.177634 | 0.989297 | 0.035319 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000965 |
BRD-K08542803-001-02-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.076708 | 6.986016 | 0.647322 | 0.846628 | 1.994726 | 2.042852 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000965 |
BRD-K08547377-001-04-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.221707 | 1.193614 | 0.774962 | 0.650116 | 0.127838 | 0.208862 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000965 |
BRD-K08703257-001-13-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.353326 | 0.000331 | -0.00294 | 1 | 0.08837 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000965 |
BRD-K08799216-001-05-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.286787 | 1.117746 | 0.587277 | 0.536053 | 0.017775 | 0.038104 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000965 |
BRD-K09951645-001-11-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.522784 | 3.897917 | 0.661899 | 0.864167 | 0.631475 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000965 |
BRD-K11630072-001-13-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.382068 | 3.496284 | 0.362442 | 0.906918 | 2.322085 | 3.510006 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000965 |
BRD-K12184916-001-19-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.632129 | -2.016016 | 0.147673 | 0.68158 | 2.740459 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000965 |
BRD-K12343256-001-14-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.184263 | 1.829404 | 0.828239 | 0.461286 | 0.016446 | 0.021144 | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000965 |
BRD-K13049116-001-04-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.929261 | 0.436436 | 0.006641 | 0.979456 | 1.173305 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000965 |
BRD-K13390322-001-06-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.076638 | 5.839915 | 0.7995 | 0.693745 | 0.40004 | 0.411608 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000965 |
BRD-K13514097-001-04-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.709903 | -0.061795 | -0.092253 | 0.875234 | 0.000793 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000965 |
BRD-K13662825-001-07-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.046781 | 0.49027 | 0.325463 | 0.505155 | 0.015639 | 0.019109 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000965 |
BRD-K14109347-001-03-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.237862 | 0.349073 | 0.211369 | 0.730766 | 0.647493 | 4.11733 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000965 |
BRD-K15179879-001-03-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.128293 | 1.42192 | 0.853223 | 0.479414 | 0.030331 | 0.037364 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000965 |
BRD-K15600710-066-05-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.114135 | 3.971775 | 0.80225 | 0.630949 | 0.172275 | 0.183891 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000965 |
BRD-K16730910-001-10-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | -0.371564 | 0.608449 | 0.444813 | 0.822996 | 7.955293 | 3.191727 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000965 |
BRD-K17555800-003-02-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.843669 | -0.120722 | -0.035317 | 0.9196 | 0.127145 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000965 |
BRD-K17610631-001-03-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 4.226591 | 1.255493 | 0.810416 | 1 | 4.767912 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000965 |
BRD-K17743125-001-08-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.123955 | 1.120457 | 0.843609 | 0.718385 | 0.453775 | 0.585153 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000965 |
BRD-K18961567-001-01-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.954306 | 0.025558 | -0.016561 | 0.980178 | 2,663.755146 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000965 |
BRD-K19540840-001-09-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.353301 | 2.473168 | 0.609231 | 0.913576 | 2.779794 | 4.563959 | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000965 |
BRD-K19687926-001-04-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.205905 | 0.607255 | 0.485097 | 0.739258 | 0.517446 | 1.239955 | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000965 |
BRD-K22064724-001-01-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.094617 | 4.450339 | 0.735308 | 0.611136 | 0.154807 | 0.162279 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000965 |
BRD-K22822991-001-02-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.349882 | -1.352236 | 0.003684 | 1 | 0.000374 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000965 |
BRD-K23228615-001-02-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.810142 | 0.211192 | 0.041091 | 0.908991 | 0.119453 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000965 |
BRD-K23984367-001-07-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.155252 | 4.763994 | 0.639441 | 0.894415 | 2.97503 | 3.216509 | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000965 |
BRD-K26026438-001-01-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.284181 | 2.91008 | 0.508124 | 0.892862 | 2.35166 | 3.13878 | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000965 |
BRD-K26657438-001-15-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.012205 | -0.01291 | -0.046307 | 1 | 27,129,124,440,995,970,000 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000965 |
BRD-K28822270-001-03-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.142909 | 1.001607 | 0.755318 | 0.686647 | 0.309481 | 0.433103 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000965 |
BRD-K29905972-001-06-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.605214 | 2.317838 | 0.569751 | 0.819095 | 0.117137 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000965 |
BRD-K30577245-001-05-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.10391 | 5.295049 | 0.734075 | 0.627446 | 0.011053 | 0.01155 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000965 |
BRD-K31698212-001-02-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.522249 | 2.03648 | 0.49569 | 0.80088 | 0.17516 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000965 |
BRD-K31928526-001-02-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.78256 | -0.153064 | -0.199626 | 0.787602 | 5,631,728,741.253135 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000965 |
BRD-K33379087-001-07-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | -0.069536 | 0.553779 | 0.760038 | 0.598902 | 0.319016 | 0.252167 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000965 |
BRD-K33610132-001-02-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.29177 | 2.532456 | 0.530595 | 0.817696 | 0.823034 | 1.163157 | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000965 |
BRD-K33622447-066-01-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.494283 | 0.145969 | -0.109511 | 1 | 0.019885 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000965 |
BRD-K35520305-001-16-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.638115 | -0.160511 | -0.004845 | 0.902533 | 0.000117 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000965 |
BRD-K36627727-001-05-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.559787 | 1.737511 | 0.210936 | 0.881102 | 0.731639 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000965 |
BRD-K36788280-001-01-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.895812 | -2.747805 | -0.004194 | 0.939071 | 0.17785 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000965 |
BRD-K37379014-001-02-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.093497 | 7.546563 | 0.69141 | 0.704211 | 0.006576 | 0.006759 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000965 |
BRD-K38332599-001-01-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.09793 | 0.844619 | 0.746432 | 0.551067 | 0.07995 | 0.103489 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000965 |
BRD-K38527262-300-01-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.670427 | 0.15141 | 0.004971 | 0.839408 | 0.102192 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000965 |
BRD-K38852836-001-02-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.263333 | 2.060083 | 0.794549 | 0.529841 | 0.005114 | 0.007353 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000965 |
BRD-K39974922-001-04-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.010591 | -0.037823 | -0.000555 | 1 | 799.219817 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000965 |
BRD-K41859756-001-06-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.33154 | 3.593356 | 0.788187 | 0.535149 | 0.002938 | 0.003977 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000965 |
BRD-K42495768-001-01-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.796912 | 0.029478 | -0.084332 | 0.902027 | 0.853664 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000965 |
BRD-K42805893-001-04-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.502495 | 0.797902 | 0.252153 | 0.891708 | 1.559192 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000965 |
BRD-K42828737-001-03-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.679836 | -0.662506 | -0.092405 | 0.939173 | 0.002295 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000965 |
BRD-K43389675-001-02-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.072664 | 1.490698 | 0.785957 | 0.533113 | 0.075512 | 0.0839 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000965 |
BRD-K44227013-001-06-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.592166 | -1.073134 | 0.048958 | 0.965888 | 0.000829 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000965 |
BRD-K44408410-001-17-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.068746 | 2.858235 | 0.617277 | 0.823368 | 1.589975 | 1.674421 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000965 |
BRD-K44827188-001-06-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.974453 | 0.310662 | 0.003583 | 0.984247 | 0.012868 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000965 |
BRD-K46386702-001-02-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.337482 | 0.473142 | 0.17243 | 0.677731 | 0.091764 | 0.986774 | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000965 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.